No abstract

The lymphocyte K ϩ channel Kv1.3 constitutes an attractive pharmacological target for the selective suppression of terminally differentiated effector memory T (T EM

Atherosclerosis remains a major cause of death in the developed world despite the success of therapies that lower cholesterol and BP. The intermediate-conductance calcium-activated potassium channel KCa3.1 is expressed in multiple cell types implicated in atherogenesis, and pharmacological blockade of this channel inhibits VSMC and lymphocyte activation in rats and mice. We found that coronary vessels from patients with coronary artery disease expressed elevated levels of KCa3.1. In Apoe -/-mice, a genetic model of atherosclerosis, KCa3.1 expression was elevated in the VSMCs, macrophages, and T lymphocytes that infiltrated atherosclerotic lesions. Selective pharmacological blockade and gene silencing of KCa3.1 suppressed proliferation, migration, and oxidative stress of human VSMCs. Furthermore, VSMC proliferation and macrophage activation were reduced in KCa3.1 -/-mice. In vivo therapy with 2 KCa3.1 blockers, TRAM-34 and clotrimazole, significantly reduced the development of atherosclerosis in aortas of Apoe -/-mice by suppressing VSMC proliferation and migration into plaques, decreasing infiltration of plaques by macrophages and T lymphocytes, and reducing oxidative stress. Therapeutic concentrations of TRAM-34 in mice caused no discernible toxicity after repeated dosing and did not compromise the immune response to influenza virus. These data suggest that KCa3.1 blockers represent a promising therapeutic strategy for atherosclerosis.

Total deficiency of complement factor H (CFH) is associated with dense deposit disease and atypical hemolytic uremic syndrome. CFH is the major regulator of the alternative pathway of complement activation and its complete deficiency results in uncontrolled C3 activation through this pathway and secondary C3 deficiency. Plasma infusion, as a source of CFH, has been used with variable success to treat renal disease associated with its deficiency. However, the risks of volume and protein overload limit this therapeutic approach. In this study, we investigated the efficacy of a purified human CFH (hCFH) preparation in Cfh-gene knockout mice. These mice spontaneously develop both secondary plasma C3 deficiency and a renal abnormality characterized by massive accumulation of C3 along the glomerular basement membrane. The renal lesion is analogous to human dense deposit disease. Treatment of knockout mice with hCFH resulted in rapid normalization of plasma C3 levels and resolution of the glomerular basement membrane C3 deposition. Long-term treatment of mice with hCFH was not possible because of the development of an immune response against hCFH. Hence, we suggest that hCFH can be an effective alternative therapy to plasma infusions in patients with renal disease associated with CFH deficiency.

The voltage-gated potassium channel Kv1.3 has been recently identified as a molecular target that allows for selective pharmacological suppression of effector memory T (T(EM)) cells without affecting the function of naïve and central memory T cells. We here investigated whether PAP-1, a small molecule Kv1.3 blocker (EC50=2 nM), could suppress allergic contact dermatitis (ACD). In a rat model of ACD, we first confirmed that the infiltrating cells in the elicitation phase are indeed CD8+ CD45RC- memory T cells with high Kv1.3 expression. In accordance with its selective effect on T(EM) cells, PAP-1 did not impair sensitization, but potently suppressed oxazolone-induced inflammation by inhibiting the infiltration of CD8+ T cells and reducing the production of the inflammatory cytokines IFN-gamma, IL-2, and IL-17 when administered intraperitoneally or orally during the elicitation phase. PAP-1 was equally effective when applied topically, demonstrating that it effectively penetrates skin. We further show that PAP-1 is not a sensitizer or an irritant and exhibits no toxicity in a 28-day toxicity study. Based on these results we propose that PAP-1 could potentially be developed into a drug for the topical treatment of inflammatory skin diseases such as psoriasis.

The complete genome sequence of the hyperthermophilic archaeon Pyrococcus abyssi revealed the presence of a family B DNA polymerase (Pol I) and a family D DNA polymerase (Pol II). To extend our knowledge about euryarchaeal DNA polymerases, we cloned the genes encoding these two enzymes and expressed them in Escherichia coli. The DNA polymerases (Pol I and Pol II) were purified to homogeneity and characterized. Pol I had a molecular mass of < 90 kDa, as estimated by SDS/PAGE. The optimum pH and Mg 21 concentration of Pol I were 8.5-9.0 and 3 mM, respectively. Pol II is composed of two subunits that are encoded by two genes arranged in tandem on the P. abyssi genome. We cloned these genes and purified the Pol II DNA polymerase from an E. coli strain coexpressing the cloned genes. The optimum pH and Mg 21 concentration of Pol II were 6.5 and 15-20 mM, respectively. Both P. abyssi Pol I and Pol II have associated 3 0 !5 0 exonuclease activity although the exonuclease motifs usually found in DNA polymerases are absent in the archaeal family D DNA polymerase sequences. Sequence analysis has revealed that the small subunit of family D DNA polymerase and the Mre11 nucleases belong to the calcineurin-like phosphoesterase superfamily and that residues involved in catalysis and metal coordination in the Mre11 nuclease three-dimensional structure are strictly conserved in both families. One hypothesis is that the phosphoesterase domain of the small subunit is responsible for the 3 0 !5 0 exonuclease activity of family D DNA polymerase. These results increase our understanding of euryarchaeal DNA polymerases and are of importance to push forward the complete understanding of the DNA replication in P. abyssi.Keywords: Pyrococcus abyssi; archaea; DNA polymerase; DNA replication; exonuclease activity.DNA polymerases play a leading role in the replication and maintenance of the genome and are central to the accurate transmission of genetic information from generation to generation. While our knowledge about DNA replication in eukarya and bacteria is quite advanced [1], limited information is available on the replication mechanism in archaea, the third major domain of life [2]. Recently, comparative genomics revealed that most archaeal proteins involved in DNA replication, transcription and translation are similar to those in eukarya, although the cellular appearance and organization of archaea are more similar to bacteria. Recent investigations [3,4] revealed that within the archaeota, euryarchaeota and crenarchaeota, the two major subdomains differ in their DNA replication mechanisms. The analysis of genome sequences indicated that many euryarchaea [5][6][7] [13] indicates that several B-type DNA polymerases exist in the crenarchaeotal genomes. These findings confirm that the DNA replication mechanism of the euryarchaeal and crenarchaeal subdomains of archaea differs, and therefore opens the discussion of the evolution of DNA polymerases, a group of indispensable proteins that are central to the replication process. However, fo...

No abstract

The bioconcentration factor (BCF), a key parameter required by the REACH regulation, estimates the tendency for a xenobiotic to concentrate inside living organisms. In silico methods can be valid alternatives to costly data measurements. However, in the industrial context, these theoretical approaches may fail to predict BCF with reasonable accuracy. We analyzed whether models built on public data only have adequate performances when challenged to predict industrial compounds. A new set of 1129 compounds has been collected by merging publicly available datasets. Generative Topographic Mapping was employed to compare this chemical space with a set of new compounds issued from the industry. Some new chemotypes absent in the training set (such as siloxanes) have been detected. A new BCF model has been built using ISIDA (In SIlico design and Data Analysis) fragment descriptors, support vector regression and random forest machinelearning methods. It has been externally validated on: (i) collected data from the literature and (ii) industrial data. The latter also served as benchmark for the freely available tools VEGA, EPISuite, TEST, OPERA. New model performs (RMSE of 0.58 log BCF units) comparably to existing ones but benefits of an extended applicability, covering the industrial set chemical space (78% data coverage).